Celldex Therapeutics, Inc. Income Statement
CLDX / Health Care|15 years of annual SEC 10-K data (FY2011-FY2025)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 15 fiscal years. All figures from audited SEC 10-K filings.
Celldex Therapeutics, Inc. reported $2M in revenue and $259M in net loss for FY2025. Revenue has declined at a 15.1% compound annual rate over the past 14 years.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 0.40 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.5M | $7.0M | $6.9M | $2.4M | $4.7M | $7.4M | $3.6M | $6.8M | $1.5M | $6.8M | $5.5M | $3.6M | $4.1M | $11.2M | $15.2M |
| Cost of Revenue | $200.0K | $200.0K | $300.0K | $100.0K | $100.0K | $200.0K | $100.0K | $1.6M | $700.0K | $1.6M | - | - | - | - | - |
| SG&A Expense | $43.8M | $38.5M | $30.9M | $27.2M | $20.5M | $14.5M | $15.4M | $36.0M | $25.0M | $36.0M | $33.8M | $20.6M | $14.8M | $10.0M | $17.1M |
| R&D Expense | $245.1M | $163.6M | $118.0M | $82.3M | $53.3M | $42.5M | $42.7M | $102.7M | $96.2M | $102.7M | $100.2M | $104.4M | $67.4M | $47.4M | $26.2M |
| Operating Income | -$287.4M | -$195.1M | -$154.5M | -$115.2M | -$71.2M | -$63.4M | -$55.0M | -$132.9M | -$121.5M | -$132.9M | -$129.5M | -$122.4M | -$81.4M | -$58.1M | -$36.9M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | $927.0K | $1.6M | $452.0K |
| Income Tax | $0 | $0 | $0 | - | -$227.0K | -$1.2M | - | -$24.3M | -$24.3M | - | - | - | $0 | $0 | -$529.0K |
| Net Income | -$258.8M | -$157.9M | -$141.4M | - | - | - | - | - | - | - | - | - | - | - | - |
| EPS (Basic) | -$3.90 | -$2.45 | -$2.92 | -$2.40 | -$1.64 | -$2.02 | -$3.51 | - | - | - | - | - | - | - | - |
| EPS (Diluted) | -$3.90 | -$2.45 | -$2.92 | -$2.40 | -$1.64 | -$2.02 | -$3.51 | -$18.99 | -$1.31 | -$18.99 | -$1.31 | -$1.32 | -$1.02 | -$1.02 | -$1.84 |
| Shares Outstanding | 66.5M | 66.4M | 55.9M | 47.2M | 46.7M | 39.6M | 17.0M | 9.2M | 120.5M | 120.5M | 98.7M | 89.6M | 89.2M | 64.4M | 32.1M |
| Operating Margin | -18599.8% | -2778.9% | -2245.3% | -4889.0% | -1531.8% | -854.1% | -1540.2% | -1958.7% | -7922.2% | -1958.7% | -2363.9% | -3414.1% | -1981.1% | -518.5% | -242.8% |
| Profit Margin | -16748.0% | -2248.8% | -2054.8% | - | - | - | - | - | - | - | - | - | - | - | - |